AMGN - 3 Reasons Why Amgen Could Actually Acquire Alexion
Is a major biotech buyout in the works? Spanish television network Intereconomia recently reported that Amgen (NASDAQ: AMGN) is in discussions to acquire Alexion Pharmaceuticals (NASDAQ: ALXN). Intereconomia cited unnamed sources that said a deal could be announced soon, with Amgen potentially offering around $200 per share for Alexion, which would translate to close to $45 billion.
These are only unconfirmed rumors at this point. But Mizuho analyst Salim Syed thinks that the possibility of a deal happening "doesn't sound too crazy."
I agree. Here are three reasons why Amgen actually could move forward with an acquisition of Alexion.